CSIMarket
 


Synaptogenix Inc   (SNPX)
Other Ticker:  
 

Cumulative Synaptogenix Inc 's Working Capital Ratio for Trailing Twelve Months Period

SNPX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SNPX Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -57.46 % -18.96 % 90.76 % -34.19 % -32.14 %
Y / Y Current Assets Growth 18.34 % 13.05 % 12.91 % 8.68 % -15.49 %
Working Capital Ratio for Trailing Twelve Months Period 41.58 35.93 33.85 38.83 31.39
Total Ranking # 80 # 76 # 39 # 27 # 59
Seq. Current Liabilities Growth -42.68 % -60.27 % -2.74 % 92.04 % 9.2 %
Seq. Current Assets Growth -3.22 % -8.47 % -5.39 % 41.19 % -7.54 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Synaptogenix Inc Current Assets average increased by 18.34% in III. Quarter year on year, while Current Liabilities plummeted to $ 0 millions, this led to increase in in Synaptogenix Inc 's Working Capital Ratio for Trailing Twelve Months Period to 41.58, Working Capital Ratio for Trailing Twelve Months Period remained below Synaptogenix Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry Synaptogenix Inc achieved highest Working Capital Ratio for Trailing Twelve Months Period. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about SNPX
Working Capital Ratio SNPX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 0
Sector # 0
S&P 500 # 1


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
38.83 28.74 19.62
(Dec 31 2022)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Cincor Pharma Inc   104.35 
Barinthus Biotherapeutics Plc  71.78 
Third Harmonic Bio Inc   60.39 
Acelyrin Inc   58.37 
Altimmune Inc   54.59 
Essa Pharma inc   53.17 
Xbiotech Inc   49.30 
Synaptogenix Inc   47.12 
Nuvation Bio Inc   46.03 
Greenwich Lifesciences Inc   42.70 
Moonlake Immunotherapeutics  38.96 
Merrimack Pharmaceuticals Inc  37.19 
Atea Pharmaceuticals Inc   37.11 
Tyra Biosciences Inc   37.03 
Aptinyx Inc   34.56 
Ars Pharmaceuticals Inc   34.41 
Rayzebio Inc   34.39 
Morphic Holding inc   32.25 
Cocrystal Pharma Inc   32.01 
Karuna Therapeutics Inc   32.00 
Aprea Therapeutics Inc   29.68 
Gh Research Plc  29.57 
Dice Therapeutics Inc   29.08 
Atossa Therapeutics Inc   28.99 
Design Therapeutics Inc   28.09 
Eliem Therapeutics Inc   27.09 
Mineralys Therapeutics Inc   27.08 
Briacell Therapeutics Corp   26.16 
Imago Biosciences Inc   25.95 
Xenon Pharmaceuticals Inc   25.51 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com